{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T17:09:05Z","timestamp":1747156145800},"reference-count":87,"publisher":"Georg Thieme Verlag KG","issue":"02","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Neurol"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Accumulating evidence in the third year of the global pandemic suggests that coronavirus disease 2019 (COVID-19) can cause neuromuscular complications during or after the acute phase of infection. Direct viral infection and immune-mediated mechanisms have been hypothesized. Furthermore, in patients with underlying autoimmune neuromuscular diseases, COVID-19 infection may trigger a disease flare. COVID-19 vaccines appear to be safe and effective at preventing severe illness from COVID-19. Certain vaccines are associated with an increased risk of Guillain-Barr\u00e9 syndrome and possibly Bell's palsy, but the absolute incidence is low, and benefits likely outweigh the risks. Newer prophylactic therapies and treatments are also becoming available for patients who may not mount a sufficient response to vaccination or have contraindications. In this article, we discuss the current available evidence on neuromuscular complications of COVID-19 and clinical considerations regarding vaccination.<\/jats:p>","DOI":"10.1055\/s-0043-1767711","type":"journal-article","created":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T23:10:55Z","timestamp":1680304255000},"page":"251-259","source":"Crossref","is-referenced-by-count":1,"title":["Neuromuscular Complications of COVID-19: Evidence from the Third Year of the Global Pandemic"],"prefix":"10.1055","volume":"43","author":[{"given":"Joome","family":"Suh","sequence":"additional","affiliation":[{"name":"Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Amato","sequence":"additional","affiliation":[{"name":"Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2023,3,31]]},"reference":[{"issue":"07","key":"ref1","doi-asserted-by":"crossref","first-page":"e274","DOI":"10.1097\/INF.0000000000003146","article-title":"First report of SARS-CoV-2 detection in cerebrospinal fluid in a child with Guillain-Barr\u00e9 syndrome","volume":"40","author":"N M Ara\u00fajo","year":"2021","journal-title":"Pediatr Infect Dis J"},{"issue":"05","key":"ref2","doi-asserted-by":"crossref","first-page":"e601","DOI":"10.1212\/WNL.0000000000009619","article-title":"Miller Fisher syndrome and polyneuritis cranialis in COVID-19","volume":"95","author":"C Guti\u00e9rrez-Ortiz","year":"2020","journal-title":"Neurology"},{"issue":"02","key":"ref3","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/CND.0000000000000322","article-title":"Acute motor axonal neuropathy related to COVID-19 infection: a new diagnostic overview","volume":"22","author":"C Petrelli","year":"2020","journal-title":"J Clin Neuromuscul Dis"},{"issue":"12","key":"ref4","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1136\/jnnp-2020-324279","article-title":"Antiganglioside antibodies in Guillain-Barr\u00e9 syndrome associated with SARS-CoV-2 infection","volume":"91","author":"C Civardi","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"05","key":"ref5","doi-asserted-by":"crossref","first-page":"e781","DOI":"10.1212\/NXI.0000000000000781","article-title":"Guillain-Barr\u00e9 syndrome: the first documented COVID-19-triggered autoimmune neurologic disease: more to come with myositis in the offing","volume":"7","author":"M C Dalakas","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"05","key":"ref6","doi-asserted-by":"crossref","first-page":"105960","DOI":"10.1016\/j.ijantimicag.2020.105960","article-title":"Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection","volume":"55","author":"J Fantini","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"P Zhou","year":"2020","journal-title":"Nature"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"197983","DOI":"10.1016\/j.virusres.2020.197983","article-title":"Genomic characterization of a novel virulent phage infecting Shigella flexneri and isolated from sewage","volume":"283","author":"H Lu","year":"2020","journal-title":"Virus Res"},{"issue":"05","key":"ref9","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s12192-020-01145-6","article-title":"SARS-CoV-2 and Guillain-Barr\u00e9 syndrome: molecular mimicry with human heat shock proteins as potential pathogenic mechanism","volume":"25","author":"G Lucchese","year":"2020","journal-title":"Cell Stress Chaperones"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"110342","DOI":"10.1016\/j.mehy.2020.110342","article-title":"NCAM protein and SARS-COV-2 surface proteins: in-silico hypothetical evidence for the immunopathogenesis of Guillain-Barr\u00e9 syndrome","volume":"145","author":"S Morsy","year":"2020","journal-title":"Med Hypotheses"},{"issue":"02","key":"ref11","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1093\/brain\/awaa433","article-title":"Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barr\u00e9 syndrome","volume":"144","author":"S Keddie","year":"2021","journal-title":"Brain"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"e189","DOI":"10.1017\/S0950268820001910","article-title":"Frequency of five unusual presentations in patients with COVID-19: results of the UMC-19-S1","volume":"148","author":"\u00d2 Mir\u00f3","year":"2020","journal-title":"Epidemiol Infect"},{"issue":"12","key":"ref13","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1038\/s41591-021-01556-7","article-title":"Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection","volume":"27","author":"M Patone","year":"2021","journal-title":"Nat Med"},{"issue":"11","key":"ref14","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1093\/brain\/awab279","article-title":"Guillain-Barr\u00e9 syndrome after SARS-CoV-2 infection in an international prospective cohort study","volume":"144","author":"L WG Luijten","year":"2021","journal-title":"Brain"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"117114","DOI":"10.1016\/j.jns.2020.117114","article-title":"COVID-19-related and not related Guillain-Barr\u00e9 syndromes share the same management pitfalls during lock down: the experience of Liguria region in Italy","volume":"418","author":"M Garnero","year":"2020","journal-title":"J Neurol Sci"},{"issue":"04","key":"ref16","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1007\/s00415-020-09911-3","article-title":"Guillain-Barr\u00e9 syndrome in the COVID-19 era: just an occasional cluster?","volume":"268","author":"G L Gigli","year":"2021","journal-title":"J Neurol"},{"issue":"07","key":"ref17","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1136\/jnnp-2020-324837","article-title":"Guillain-Barr\u00e9 syndrome and COVID-19: an observational multicentre study from two Italian hotspot regions","volume":"92","author":"M Filosto","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"02","key":"ref18","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/jns.12439","article-title":"Guillain-Barr\u00e9 syndrome decreases in Singapore during the COVID-19 pandemic","volume":"26","author":"T Umapathi","year":"2021","journal-title":"J Peripher Nerv Syst"},{"issue":"05","key":"ref19","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1093\/brain\/awab070","article-title":"Reply: Guillain-Barr\u00e9 syndrome, SARS-CoV-2 and molecular mimicry and Ongoing challenges in unravelling the association between COVID-19 and Guillain-Barr\u00e9 syndrome and Unclear association between COVID-19 and Guillain-Barr\u00e9 syndrome and currently available data regarding the potential association between COVID-19 and Guillain-Barr\u00e9 syndrome","volume":"144","author":"M P Lunn","year":"2021","journal-title":"Brain"},{"issue":"03","key":"ref20","doi-asserted-by":"crossref","first-page":"e1146","DOI":"10.1212\/NXI.0000000000001146","article-title":"Peripheral neuropathy evaluations of patients with prolonged long COVID","volume":"9","author":"A L Oaklander","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"08","key":"ref21","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1007\/s10072-022-06136-2","article-title":"Autonomic dysfunction in non-critically ill COVID-19 patients during the acute phase of disease: an observational, cross-sectional study","volume":"43","author":"I Scala","year":"2022","journal-title":"Neurol Sci"},{"issue":"12","key":"ref22","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1097\/j.pain.0000000000002639","article-title":"Post-acute sensory neurological sequelae in patients with severe acute respiratory syndrome coronavirus 2 infection: the COVID-PN observational cohort study","volume":"163","author":"C U Odozor","year":"2022","journal-title":"Pain"},{"issue":"04","key":"ref23","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/mus.27458","article-title":"Small fiber neuropathy associated with SARS-CoV-2 infection","volume":"65","author":"R MC Abrams","year":"2022","journal-title":"Muscle Nerve"},{"issue":"03","key":"ref24","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/ana.26286","article-title":"Multisystem involvement in post-acute sequelae of coronavirus disease 19","volume":"91","author":"P Novak","year":"2022","journal-title":"Ann Neurol"},{"issue":"01","key":"ref25","doi-asserted-by":"crossref","first-page":"14042","DOI":"10.1038\/s41598-021-93546-5","article-title":"Clinical characterization of dysautonomia in long COVID-19 patients","volume":"11","author":"N Barizien","year":"2021","journal-title":"Sci Rep"},{"issue":"11","key":"ref26","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1097\/j.pain.0000000000002051","article-title":"ACE2 and SCARF expression in human dorsal root ganglion nociceptors: implications for SARS-CoV-2 virus neurological effects","volume":"161","author":"S Shiers","year":"2020","journal-title":"Pain"},{"issue":"08","key":"ref27","doi-asserted-by":"crossref","first-page":"e849","DOI":"10.1212\/WNL.0000000000012344","article-title":"Skeletal muscle and peripheral nerve histopathology in COVID-19","volume":"97","author":"J Suh","year":"2021","journal-title":"Neurology"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000011881","article-title":"Guillain-Barr\u00e9 syndrome in the placebo and active arms of a COVID-19 vaccine clinical trial: temporal associations do not imply causality","author":"A M M\u00e1rquez Loza","year":"2021","journal-title":"Neurology"},{"issue":"16","key":"ref29","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1001\/jama.2021.16496","article-title":"Association of receipt of the Ad26.COV2.S COVID-19 vaccine with presumptive Guillain-Barr\u00e9 syndrome, February-July 2021","volume":"326","author":"E J Woo","year":"2021","journal-title":"JAMA"},{"issue":"04","key":"ref30","doi-asserted-by":"crossref","first-page":"e228879","DOI":"10.1001\/jamanetworkopen.2022.8879","article-title":"Incidence of Guillain-Barr\u00e9 syndrome after COVID-19 vaccination in the Vaccine Safety Datalink","volume":"5","author":"K E Hanson","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"07","key":"ref31","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s40261-022-01164-4","article-title":"Guillain-Barr\u00e9 syndrome associated with COVID-19 vaccines: a perspective from spontaneous report data","volume":"42","author":"M Atzenhoffer","year":"2022","journal-title":"Clin Drug Investig"},{"issue":"02","key":"ref32","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1093\/brain\/awac067","article-title":"COVID-19 vaccination and Guillain-Barr\u00e9 syndrome: analyses using the National Immunoglobulin Database","volume":"146","author":"R YS Keh","year":"2023","journal-title":"Brain"},{"issue":"02","key":"ref33","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/ana.26143","article-title":"Guillain-Barr\u00e9 syndrome following ChAdOx1-S\/nCoV-19 vaccine","volume":"90","author":"B V Maramattom","year":"2021","journal-title":"Ann Neurol"},{"issue":"05","key":"ref34","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/ana.26218","article-title":"Guillain-Barr\u00e9 syndrome in an Australian state using both mRNA and adenovirus-vector SARS-CoV-2 vaccines","volume":"90","author":"J Osowicki","year":"2021","journal-title":"Ann Neurol"},{"issue":"32","key":"ref35","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.15585\/mmwr.mm7032e4","article-title":"Use of COVID-19 vaccines after reports of adverse events among adult recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 vaccines (Pfizer-BioNTech and Moderna): update from the Advisory Committee on Immunization Practices - United States, July 2021","volume":"70","author":"H G Rosenblum","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"11","key":"ref39","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1001\/jamaneurol.2021.3287","article-title":"Rate of recurrent Guillain-Barr\u00e9 syndrome after mRNA COVID-19 vaccine BNT162b2","volume":"78","author":"S Shapiro Ben David","year":"2021","journal-title":"JAMA Neurol"},{"issue":"01","key":"ref40","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S1473-3099(21)00451-5","article-title":"Bell's palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study","volume":"22","author":"E YF Wan","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"09","key":"ref41","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/S1473-3099(21)00323-6","article-title":"Bell's palsy and SARS-CoV-2 vaccines-an unfolding story - authors' reply","volume":"21","author":"A Ozonoff","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.ijid.2021.08.071","article-title":"Facial nerve palsy following the administration of COVID-19 mRNA vaccines: analysis of a self-reporting database","volume":"111","author":"K Sato","year":"2021","journal-title":"Int J Infect Dis"},{"issue":"08","key":"ref43","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1001\/jamaoto.2021.1259","article-title":"Association of COVID-19 vaccination and facial nerve palsy: a case-control study","volume":"147","author":"A Shemer","year":"2021","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"01","key":"ref44","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.cmi.2021.09.018","article-title":"Real-world safety data for the Pfizer BNT162b2 SARS-CoV-2 vaccine: historical cohort study","volume":"28","author":"D Shasha","year":"2022","journal-title":"Clin Microbiol Infect"},{"issue":"09","key":"ref45","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1001\/jamainternmed.2021.2219","article-title":"Association of facial paralysis with mRNA COVID-19 vaccines: a disproportionality analysis using the World Health Organization Pharmacovigilance Database","volume":"181","author":"L Renoud","year":"2021","journal-title":"JAMA Intern Med"},{"issue":"06","key":"ref46","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/mus.26689","article-title":"Factors associated with acute exacerbations of myasthenia gravis","volume":"60","author":"R R Gummi","year":"2019","journal-title":"Muscle Nerve"},{"issue":"02","key":"ref47","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/mus.27324","article-title":"COVID-19 in patients with myasthenia gravis: epidemiology and disease course","volume":"64","author":"P Businaro","year":"2021","journal-title":"Muscle Nerve"},{"issue":"16","key":"ref48","doi-asserted-by":"crossref","first-page":"e2109","DOI":"10.1212\/WNL.0000000000011669","article-title":"Impact of coronavirus disease 2019 in a French cohort of myasthenia gravis","volume":"96","author":"G Sol\u00e9","year":"2021","journal-title":"Neurology"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"117362","DOI":"10.1016\/j.jns.2021.117362","article-title":"Electronic health record derived-impact of COVID-19 on myasthenia gravis","volume":"423","author":"B Roy","year":"2021","journal-title":"J Neurol Sci"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"802559","DOI":"10.3389\/fneur.2022.802559","article-title":"COVID-19 outcomes in myasthenia gravis patients: analysis from electronic health records in the United States","volume":"13","author":"Y Kim","year":"2022","journal-title":"Front Neurol"},{"issue":"12","key":"ref51","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/S1474-4422(20)30413-0","article-title":"COVID-19-associated risks and effects in myasthenia gravis (CARE-MG)","volume":"19","author":"S Muppidi","year":"2020","journal-title":"Lancet Neurol"},{"issue":"10","key":"ref52","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1111\/ene.14951","article-title":"Predictive factors for a severe course of COVID-19 infection in myasthenia gravis patients with an overall impact on myasthenic outcome status and survival","volume":"28","author":"M Jakub\u00edkov\u00e1","year":"2021","journal-title":"Eur J Neurol"},{"issue":"01","key":"ref53","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1136\/annrheumdis-2021-220549","article-title":"B-cell targeted therapy is associated with severe COVID-19 among patients with inflammatory arthritides: a 1-year multicentre study in 1116 successive patients receiving intravenous biologics","volume":"81","author":"R Felten","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"ref54","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1177\/0885066620954787","article-title":"Reducing the risk and impact of brachial plexus injury sustained from prone positioning - a clinical commentary","volume":"35","author":"A I Simpson","year":"2020","journal-title":"J Intensive Care Med"},{"issue":"06","key":"ref55","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1001\/jamaneurol.2021.0688","article-title":"Outcomes and risk factors associated with SARS-CoV-2 infection in a North American Registry of patients with multiple sclerosis","volume":"78","author":"A Salter","year":"2021","journal-title":"JAMA Neurol"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"100639","DOI":"10.1016\/j.eclinm.2020.100639","article-title":"Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: a systematic review and meta-analysis","volume":"29","author":"M B Malas","year":"2020","journal-title":"EClinicalMedicine"},{"issue":"18","key":"ref57","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1212\/WNL.0000000000010651","article-title":"Clinical reasoning: therapeutic considerations in myasthenic crisis due to COVID-19 infection","volume":"95","author":"P Hoang","year":"2020","journal-title":"Neurology"},{"issue":"01","key":"ref58","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1186\/s13054-020-03070-7","article-title":"First do no harm-beware the risk of therapeutic plasma exchange in severe COVID-19","volume":"24","author":"K Stahl","year":"2020","journal-title":"Crit Care"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"116803","DOI":"10.1016\/j.jns.2020.116803","article-title":"Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic","volume":"412","author":"S Jacob","year":"2020","journal-title":"J Neurol Sci"},{"issue":"03","key":"ref60","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/mus.27179","article-title":"Doctor-Should I get the COVID-19 vaccine? Infection and immunization in individuals with neuromuscular disorders","volume":"63","author":"S A \u017divkovi\u0107","year":"2021","journal-title":"Muscle Nerve"},{"issue":"08","key":"ref61","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1111\/ene.15348","article-title":"Safety and tolerability of SARS-CoV-2 vaccination in patients with myasthenia gravis: a multicenter experience","volume":"29","author":"A Farina","year":"2022","journal-title":"Eur J Neurol"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"120225","DOI":"10.1016\/j.jns.2022.120225","article-title":"Flare of myasthenia gravis induced by COVID-19 vaccines","volume":"436","author":"K Ishizuchi","year":"2022","journal-title":"J Neurol Sci"},{"issue":"03","key":"ref63","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.nmd.2022.01.013","article-title":"Early safety and tolerability profile of the BNT162b2 COVID-19 vaccine in myasthenia gravis","volume":"32","author":"I Lotan","year":"2022","journal-title":"Neuromuscul Disord"},{"issue":"10","key":"ref66","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1136\/annrheumdis-2021-220656","article-title":"High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases","volume":"80","author":"J A Ruddy","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"01","key":"ref67","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1136\/rmdopen-2022-002308","article-title":"Very low rate of humoral response after a third COVID-19 vaccine dose in patients with autoimmune diseases treated with rituximab and non-responders to two doses","volume":"8","author":"S Bitoun","year":"2022","journal-title":"RMD Open"},{"issue":"03","key":"ref68","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/S2665-9913(21)00394-5","article-title":"Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study","volume":"4","author":"I Jyssum","year":"2022","journal-title":"Lancet Rheumatol"},{"issue":"08","key":"ref70","doi-asserted-by":"crossref","first-page":"e1060","DOI":"10.1212\/WNL.0000000000009937","article-title":"Neurologic manifestations in hospitalized patients with COVID-19: the ALBACOVID registry","volume":"95","author":"C M Romero-S\u00e1nchez","year":"2020","journal-title":"Neurology"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"C Huang","year":"2020","journal-title":"Lancet"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","article-title":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study","volume":"395","author":"N Chen","year":"2020","journal-title":"Lancet"},{"issue":"06","key":"ref73","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/jmv.25757","article-title":"COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis","volume":"92","author":"L Q Li","year":"2020","journal-title":"J Med Virol"},{"issue":"04","key":"ref74","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3390\/jcm9040941","article-title":"Novel coronavirus infection (COVID-19) in humans: a scoping review and meta-analysis","volume":"9","author":"I J Borges do Nascimento","year":"2020","journal-title":"J Clin Med"},{"issue":"11","key":"ref75","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1001\/jama.2020.1585","article-title":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China","volume":"323","author":"D Wang","year":"2020","journal-title":"JAMA"},{"issue":"06","key":"ref76","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1001\/jamaneurol.2020.1127","article-title":"Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China","volume":"77","author":"L Mao","year":"2020","journal-title":"JAMA Neurol"},{"issue":"18","key":"ref77","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China","volume":"382","author":"W J Guan","year":"2020","journal-title":"N Engl J Med"},{"issue":"03","key":"ref78","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/SHK.0000000000001725","article-title":"Rhabdomyolysis is associated with in-hospital mortality in patients with COVID-19","volume":"56","author":"Y Geng","year":"2021","journal-title":"Shock"},{"issue":"01","key":"ref79","first-page":"e12552","article-title":"Rhabdomyolysis in COVID-19 patients: a retrospective observational study","volume":"13","author":"M W Haroun","year":"2021","journal-title":"Cureus"},{"issue":"24","key":"ref80","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1056\/NEJMc2031085","article-title":"COVID-19-associated myopathy caused by Type I interferonopathy","volume":"383","author":"G S Manzano","year":"2020","journal-title":"N Engl J Med"},{"issue":"03","key":"ref81","doi-asserted-by":"crossref","first-page":"E57","DOI":"10.1002\/mus.27003","article-title":"COVID-19-associated myositis with severe proximal and bulbar weakness","volume":"62","author":"H Zhang","year":"2020","journal-title":"Muscle Nerve"},{"issue":"01","key":"ref82","doi-asserted-by":"crossref","first-page":"E9","DOI":"10.1002\/mus.27105","article-title":"COVID-19-associated myositis may be dermatomyositis","volume":"63","author":"J Tanboon","year":"2021","journal-title":"Muscle Nerve"},{"issue":"04","key":"ref83","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.1093\/rheumatology\/keab872","article-title":"Anti-NXP2 antibody-positive dermatomyositis developed after COVID-19 manifesting as type I interferonopathy","volume":"61","author":"Y Okada","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"08","key":"ref84","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1001\/jamaneurol.2021.2004","article-title":"Association between SARS-CoV-2 infection and immune-mediated myopathy in patients who have died","volume":"78","author":"T Aschman","year":"2021","journal-title":"JAMA Neurol"},{"issue":"01","key":"ref85","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1001\/jamainternmed.2020.6278","article-title":"Diaphragm pathology in critically ill patients with COVID-19 and postmortem findings from 3 medical centers","volume":"181","author":"Z Shi","year":"2021","journal-title":"JAMA Intern Med"},{"issue":"04","key":"ref86","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1093\/jnen\/nlaa155","article-title":"Muscle biopsy findings in a case of SARS-CoV-2-associated muscle injury","volume":"80","author":"J E Hooper","year":"2021","journal-title":"J Neuropathol Exp Neurol"},{"issue":"04","key":"ref87","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/ana.26318","article-title":"COVID-19-associated critical illness myopathy with direct viral effects","volume":"91","author":"D Dodig","year":"2022","journal-title":"Ann Neurol"},{"issue":"03","key":"ref88","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1002\/jcsm.12989","article-title":"Development and early diagnosis of critical illness myopathy in COVID-19 associated acute respiratory distress syndrome","volume":"13","author":"B Rodriguez","year":"2022","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"07","key":"ref89","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1016\/j.clinph.2021.03.016","article-title":"Critical illness polyneuropathy, myopathy and neuronal biomarkers in COVID-19 patients: a prospective study","volume":"132","author":"R Frithiof","year":"2021","journal-title":"Clin Neurophysiol"},{"issue":"08","key":"ref90","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/j.clinph.2020.06.003","article-title":"Critical illness myopathy as a consequence of COVID-19 infection","volume":"131","author":"H Tankisi","year":"2020","journal-title":"Clin Neurophysiol"},{"issue":"04","key":"ref91","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/mus.27681","article-title":"COVID-19 Vaccination in Autoimmune Diseases (COVAD) study: vaccine safety in idiopathic inflammatory myopathies","volume":"66","author":"A Gil-Vila","year":"2022","journal-title":"Muscle Nerve"},{"issue":"01","key":"ref92","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/art.41924","article-title":"Disease flare and reactogenicity in patients with rheumatic and musculoskeletal diseases following two-dose SARS-CoV-2 messenger RNA vaccination","volume":"74","author":"C M Connolly","year":"2022","journal-title":"Arthritis Rheumatol"},{"issue":"07","key":"ref93","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1007\/s11739-022-03028-3","article-title":"Relapses of idiopathic inflammatory myopathies after vaccination against COVID-19: a real-life multicenter Italian study","volume":"17","author":"E Conticini","year":"2022","journal-title":"Intern Emerg Med"}],"container-title":["Seminars in Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0043-1767711.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,10]],"date-time":"2023-12-10T02:11:14Z","timestamp":1702174274000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0043-1767711"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,31]]},"references-count":87,"journal-issue":{"issue":"02","published-online":{"date-parts":[[2023,6,28]]},"published-print":{"date-parts":[[2023,4]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0043-1767711","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0271-8235","1098-9021"],"issn-type":[{"value":"0271-8235","type":"print"},{"value":"1098-9021","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,31]]}}}